Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (1176)	9/21/1999 12:08:00 PM
From: LLCF	Respond to of 3202

OOpppsss... better make another new map! Genome Project better get some more cash.... this could take.... hmmmm... 100 years???: Tuesday September 21, 9:42 am Eastern Time Company Press Release Incyte Reaches New Milestone in Assembling Complete Set of Human Genes New Research Indicates Human Gene Count Larger Than Suspected MIAMI--(BUSINESS WIRE)--September 21, 1999--Incyte Pharmaceuticals, Inc. (Nasdaq:INCY - news), a leading provider of genomic technologies, announced today that the number of human genes is nearly twice as large as earlier estimates. Incyte's latest research now indicates that the genome contains about 140,000 human genes. Previous estimates placed the number at 60,000 to 80,000. This latest finding is an important milestone in the race to determine the number of human genes, as well as their role in disease. The discovery will ultimately help researchers increase the precision with which the medical community will be able to diagnose and treat illnesses that have been difficult to understand in the past. Incyte, which already has the most comprehensive library of biological information in the world, considers this latest data discovery to be another valuable tool for scientists. ''We know that identifying all the genes in the human body, which is a finite set, will have a tremendous impact on the future of research and ultimately health care,'' said Randy Scott, president and chief scientific officer of Incyte, during a presentation at The Institute for Genomics Research (TIGR) 11th Annual International Genome Sequencing and Analysis Conference in Miami. ''Being one step closer to identifying all of the genes in the human genome is significant in determining the role of genes in the diagnosis, prevention and treatment of disease.'' Incyte's scientists made the discovery through analysis of the nearly 5 million human gene sequences found in its LifeSeq® Gold database. That database is used by scientists who are studying gene function. They use the data to improve their understanding of the genetic code and its link to health and disease. This discovery is of particular value to the companies and academic institutions partnering with Incyte, which include the world's largest pharmaceutical companies, as well as the Huntsman Cancer Institute. Scott also announced the expansion of Incyte's database programs to analyze DNA variation between individuals, RNA and protein expression. Incyte now has more than 100,000 genes commercially available for microarrays-based gene expression and has begun to build what is believed to be the world's largest gene expression database. ''We're essentially taking all of the genes we've discovered and providing an integrated method for linking all of the data together for researchers,'' said Scott. ''This is a powerful tool for studying biological systems and the molecular basis of disease and it can be accessed by the entire scientific community.'' As part of its ongoing business development strategy, Incyte also is broadening its partnerships to include more academic researchers, in addition to pharmaceutical and biotechnology companies. ''Our commitment to increasing access to our wide array of products makes perfect sense,'' Scott said. ''As we look to duplicate our initial successes, it's imperative that we focus on developing new products for our current customers and identifying additional customers who recognize the value of our products and the potential results they can yield.'' The Silicon Valley-based firm has just launched its ''In Silico Partnership Program'' which will provide select academic investigators with collaborative access to Incyte's genomic databases, microarrays, reagents, and software products that are currently used in all phases of drug discovery and development. Its alliance with the Huntsman Cancer Institute was announced earlier this month and will focus on the genetic study of colon cancer in families with a high risk of developing the disease. Huntsman will use Incyte's state-of-the art microarray technology as well as the LifeSeq® Gold database. In addition, Incyte is now offering free online access to selected GEM(TM) microarray data and experiments. Each month, visitors to the site (http://www.incyte.com/gem) will be able to view biological applications of microarray technology and download data sets for analysis. About Incyte Pharmaceuticals, Inc. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, and related reagents and services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's Web site at www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements. DAK

To: LLCF who wrote (1176)	9/21/1999 12:14:00 PM
From: LLCF	Read Replies (1) \| Respond to of 3202

They're pumping their new offering: The Silicon Valley-based firm has just launched its ''In Silico Partnership Program'' which will provide select academic investigators with collaborative access to Incyte's genomic databases, microarrays, reagents, and software products that are currently used in all phases of drug discovery and development. Its alliance with the Huntsman Cancer Institute was announced earlier this month and will focus on the genetic study of colon cancer in families with a high risk of developing the disease. Huntsman will use Incyte's state-of-the art microarray technology as well as the LifeSeq® Gold database. I'll give a call and see what type of deal they are structuring.. I recall that they said at their conference call that they would structure all sorts of deals depending on the subscriber, and what they could afford. In other words, this deal is probably back-end royalty... and very little upfront. DAK